Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 704Carcinoma, Non-Small-Cell Lung 470Prostatic Neoplasms 420Neoplasms 380Multiple Myeloma 264Colorectal Neoplasms 261Lung Neoplasms 247Neoplasm Metastasis 229Melanoma 215Ovarian Neoplasms 191Leukemia, Myeloid, Acute 189Pancreatic Neoplasms 182Squamous Cell Carcinoma of Head and Neck 163Recurrence 147Carcinoma, Renal Cell 145Lymphoma 142Glioblastoma 138Lymphoma, Non-Hodgkin 135Stomach Neoplasms 128Triple Negative Breast Neoplasms 127Brain Neoplasms 124Carcinoma, Hepatocellular 123Leukemia, Lymphocytic, Chronic, B-Cell 122Uterine Cervical Neoplasms 117Head and Neck Neoplasms 117Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Urinary Bladder Neoplasms 113Lymphoma, Large B-Cell, Diffuse 105Sarcoma 102Lymphoma, Follicular 100

Interventions

atezolizumab 1Tiragolumab 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Advanced Rare Malignant Solid Neoplasm × Clear all
NCT05715281 2025-11-25

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
12 enrolled
Other solid neoplasm

Advanced Rare Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡